AmericasENPublic regulatory overview
Colombia
Market Overview Population: Approximately 52 million (2024), one of the largest economies in the Andean region Healthcare system: The SGSSS (Sistema General de Seguridad Social en...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAStrong benefitFDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Colombia
- Product line: Medical devices
- Regulator / source: Regulatory maturity: Moderate — the INVIMA framework is generally sound and references EU/GHTF principles; it has been continuously improved in recent years. The SIRIS online system has improved transparency. However, reviewer resources are limited and review timelines for high-risk devices are lengthy
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulatory maturity: Moderate — the INVIMA framework is generally sound and references EU/GHTF principles; it has been continuously improved in recent years. The SIRIS online system has improved transparency. However, reviewer resources are limited and review timelines for high-risk devices are lengthy
- Key fees: Market characteristics: The medical device market is valued at approximately USD 1.5–2 billion per year, with a high import dependency (approximately 85%). The market is concentrated in Bogotá, Medellín, and Cali. Government procurement (including EPSs and public hospitals) accounts for approximately 60% of the market. Both medicines and devices are regulated by INVIMA under a unified framework
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 52 million (2024), one of the largest economies in the Andean region
- Healthcare system: The SGSSS (Sistema General de Seguridad Social en Salud) universal health insurance framework operates through a two-tier structure of EPSs (Entidades Promotoras de Salud, insurance entities) and IPSs (Instituciones Prestadoras de Servicios, service delivery institutions); the public contributory/subsidized regime and the private contributory regime operate in parallel
- Market characteristics: The medical device market is valued at approximately USD 1.5–2 billion per year, with a high import dependency (approximately 85%). The market is concentrated in Bogotá, Medellín, and Cali. Government procurement (including EPSs and public hospitals) accounts for approximately 60% of the market. Both medicines and devices are regulated by INVIMA under a unified framework
- Regulatory maturity: Moderate — the INVIMA framework is generally sound and references EU/GHTF principles; it has been continuously improved in recent years. The SIRIS online system has improved transparency. However, reviewer resources are limited and review timelines for high-risk devices are lengthy
Regulatory Authority
- Primary authority: INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), under the Ministerio de Salud y Protección Social
- Official portal: https://www.invima.gov.co; electronic filing system: SIRIS (https://siris.invima.gov.co)
- Key regulations:
- Decreto 4725/2005 (core regulation on medical device and IVD registration)
- Resolución 4816/2008 (vigilance/pharmacovigilance system)
- Resolución 2013 series (classification and technical requirements updates)
- Decreto 1071/2015 (simplified administrative procedures)
- Resolución 3100/2019 (healthcare technology conditions)
- Ongoing Circulares Técnicas (technical circulars)
Device Classification
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Clase I | Low risk | EU Class I / FDA Class I | Self-certification; INVIMA notification; simplest process |
| Clase IIA | Low-moderate risk | EU Class IIa / FDA Class II | Registro Sanitario; standard review |
| Clase IIB | Moderate-high risk | EU Class IIb / FDA Class II-III | Registro Sanitario; more stringent review |
| Clase III | High risk | EU Class III / FDA Class III | Registro Sanitario; most stringent; complete clinical evidence required |
| Clase IV | Highest risk | EU Class III (most stringent) / FDA Class III PMA | Very limited category (e.g., certain long-term implants); most stringent review |
Note: Decreto 4725/2005 sets out the classification rules. In practice, the boundary between Clase I and Clase IIA can be ambiguous; classification should be confirmed in advance. IVDs are classified separately according to a specific list.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.